HENRY FORD HEALTH SYSTEM
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1915-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.henryford.com
Clinical Trials
266
Active:11
Completed:149
Trial Phases
6 Phases
Early Phase 1:6
Phase 1:10
Phase 2:27
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (209 trials with phase data)• Click on a phase to view related trials
Not Applicable
125 (59.8%)Phase 4
30 (14.4%)Phase 2
27 (12.9%)Phase 3
11 (5.3%)Phase 1
10 (4.8%)Early Phase 1
6 (2.9%)Restorative Early Sleep Treatment After the Emergency Department
Not Applicable
Recruiting
- Conditions
- InsomniaNightmares Associated With Trauma and StressNightmaresPTSD - Post Traumatic Stress Disorder
- First Posted Date
- 2025-08-13
- Last Posted Date
- 2025-08-13
- Lead Sponsor
- Henry Ford Health System
- Target Recruit Count
- 80
- Registration Number
- NCT07121270
- Locations
- 🇺🇸
Henry Ford Hospital System, Detroit, Michigan, United States
Bright Light Therapy on Sleep Health in Lung Cancer Patients
Not Applicable
Recruiting
- Conditions
- Lung Cancers
- First Posted Date
- 2025-07-14
- Last Posted Date
- 2025-07-14
- Lead Sponsor
- Henry Ford Health System
- Target Recruit Count
- 20
- Registration Number
- NCT07064395
- Locations
- 🇺🇸
Henry Ford Health System, Detroit, Michigan, United States
Efficacy of Ketorolac for Postoperative Pain Management in Hip Arthroscopy: A Prospective Double-Blinded Randomized Controlled Trial
Phase 4
Recruiting
- Conditions
- Femoracetabular ImpingementHip Arthroscopy
- Interventions
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Henry Ford Health System
- Target Recruit Count
- 100
- Registration Number
- NCT07037888
- Locations
- 🇺🇸
Henry Ford Health, Detroit, Michigan, United States
Photodynamic Diagnosis of Upper Tract Urothelial Carcinoma Using Fluorescence Endoscopy and Oral 5-ALA
Phase 2
Not yet recruiting
- Conditions
- Upper Tract Urothelial Carcinoma
- Interventions
- Drug: 5-Aminolevulinic acid Hydrochloride (Gliolan®)
- First Posted Date
- 2025-04-29
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Henry Ford Health System
- Target Recruit Count
- 10
- Registration Number
- NCT06948552
- Locations
- 🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States
The Efficacy of Bakuchiol in Treating PIH
Not Applicable
Completed
- Conditions
- Post Inflammatory Hyperpigmentation
- Interventions
- Drug: Vehicle
- First Posted Date
- 2025-02-19
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- Henry Ford Health System
- Target Recruit Count
- 22
- Registration Number
- NCT06833996
- Locations
- 🇺🇸
Department of Dermatology, Henry Ford Medical Center, 3031 West Grand Boulevard,, Detroit, Michigan, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 54
- Next
News
No news found